Elicio Therapeutics 3Q 2026: EPS ($0.3) — 10-Q Summary

Elicio Therapeutics’ net loss narrowed year over year in the third quarter, as lower clinical-trial costs and a gain from changes in warrant fair value more than offset higher personnel and professional fees.Financial Highlights² Reported as “Net loss”. ³ Reported as “Net loss per common share, bas…